BioSpace News Archive

Business

IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022

IceCure Medical Ltd. today announced it will report its business and financial results as of and for the six months ended June 30, 2022 on Monday, August 15, 2022 with a press release issued at 4:00 p.m. EDT and will conduct a conference call that will take place that day at 4:30 p.m. EDT.

August 9, 2022
·
3 min read
Genetown

MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform

MilliporeSigma has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development.

August 9, 2022
·
4 min read
FDA

CereVasc Announces FDA Approval of Second IDE Study of the eShunt® System

CereVasc, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt® System in patients who develop communicating hydrocephalus post aneurysmal subarachnoid hemorrhage (paSAH).

August 9, 2022
·
2 min read
Business

Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.

August 9, 2022
·
9 min read
Business

AMYRIS, INC. REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the second quarter ended June 30, 2022.

August 9, 2022
·
24 min read
Deals

Heron Therapeutics Announces $76.5 Million Private Placement Financing

Heron Therapeutics, Inc. announced today that it has entered into a securities purchase agreement to sell in a private placement to a group of new and existing institutional investors.

August 9, 2022
·
7 min read
BioMidwest

Be The Match BioTherapies® Now Offers A Central Point of Access To Fully-Characterized Cord Blood Units for Commercial and Clinical Use

Be The Match BioTherapies® announced it is now providing cryopreserved Cord Blood Units as allogeneic cell therapy starting material for non-clinical, clinical, and commercial use.

August 9, 2022
·
3 min read
Business

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board”).

August 9, 2022
·
4 min read
Business

Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Artelo Biosciences, Inc. today reported financial and operating results for the three months ended June 30, 2022.

August 9, 2022
·
8 min read
Drug Development

Saol Therapeutics Announces First Patient Enrolled in Phase 2 COMPASS Trial Evaluating the Safety and Efficacy Profile of SL-1002 for Treatment of Knee Pain Associated with Osteoarthritis

Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the first patient has been enrolled in the company’s Phase 2 COMPASS Osteoarthritis Pain Trial.

August 9, 2022
·
5 min read